Case Report of Hepatitis C Treatment Success in Male With Decompensated Cirrhosis and Polysubstance Abuse: The Important Role of the Pharmacist in Active Care Coordination
Restricted accessCase reportFirst published online June, 2023
Case Report of Hepatitis C Treatment Success in Male With Decompensated Cirrhosis and Polysubstance Abuse: The Important Role of the Pharmacist in Active Care Coordination
This is a case report of a man with decompensated cirrhosis and polysubstance abuse that was cured of chronic hepatitis C virus (HCV) infection through pharmacist active care coordination. The patient was prescribed Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg) 1 tablet by mouth daily for 24 weeks, but finished his course 18 days late due to poor compliance and treatment interruptions. The active role of the clinical pharmacist in the hepatology clinic facilitated the patient’s ongoing engagement in care, leading to treatment success.
ZibbellJEAsherAKPatelRC, et al.Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States 2004 to 2014. Am J Public Health; 2018;108(2):175-181.
2.
AASLD- IDSA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed May 28, 2020.
3.
GrebelyJDalgardOConwayB, et al.Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterology Hepatology. 2018;3(3):153-161.
4.
RosenthalESNussdorfLD’AmoreA, et al.2900. High rates of experienced and witnessed opioid overdose in PWID receiving HCV treatment: data from the ANCHOR study. Open Forum Infect Dis. 2019;6(suppl 2):S83.
5.
GrebelyJMatthewsGVHellardM, et al.Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol. 2011;55(1):76-85.
6.
AspinallEJCorsonSDoyleJS, et al.Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis. 2013;57(suppl 2):S80-S89.
7.
HellardMDoyleJSSacks‐DavisRThompsonAJMcBrydeE. Eradication of hepatitis C infection: the importance of targeting people who inject drugs. Hepatology. 2014;59(2):366-369.
8.
CurryMPO’LearyJGBzowejN, et al.Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618-2628.
